Cargando…

Remdesivir-related cost-effectiveness and cost and resource use evidence in COVID-19: a systematic review

BACKGROUND: The coronavirus disease 2019 (COVID-19) pandemic has been a global health emergency since December 2019, leading to millions of deaths worldwide and placing significant pressures, including economic burden, on individual patients and healthcare systems. As of February 2022, remdesivir is...

Descripción completa

Detalles Bibliográficos
Autores principales:	Murton, Molly, Drane, Emma, Jarrett, James, Cornely, Oliver A., Soriano, Alex
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9555695/ https://www.ncbi.nlm.nih.gov/pubmed/36224452 http://dx.doi.org/10.1007/s15010-022-01930-8

Ejemplares similares

A cost of illness study of COVID-19 patients and retrospective modelling of potential cost savings when administering remdesivir during the pandemic “first wave” in a German tertiary care hospital
por: Jeck, Julia, et al.
Publicado: (2021)

Modeling the Potential Impact of Remdesivir Treatment for Hospitalized Patients with COVID-19 in Saudi Arabia on Healthcare Resource Use and Direct Hospital Costs: A Hypothetical Study
por: Ruggeri, Matteo, et al.
Publicado: (2022)

Baricitinib + remdesivir cost saving vs remdesivir for hospitalised COVID-19 patients in the USA
Publicado: (2021)

The Cost-Effectiveness of Remdesivir for Hospitalized Patients With COVID-19
por: Whittington, Melanie D., et al.
Publicado: (2022)

Remdesivir cost effective for severe COVID-19 in China
Publicado: (2021)

Remdesivir for Hospitalized COVID-19 Patients in the United States: Optimization of Health Care Resources
por: Barnieh, Lianne, et al.
Publicado: (2023)

Cost-effectiveness of remdesivir for the treatment of hospitalized patients with COVID-19: a systematic review
por: Rezapour, Aziz, et al.
Publicado: (2023)

Effects on LOS may not justify cost of remdesivir for severe COVID-19
Publicado: (2021)

Cost-effectiveness of Remdesivir and Dexamethasone for COVID-19 Treatment in South Africa
por: Jo, Youngji, et al.
Publicado: (2021)

Cost-Effectiveness of Remdesivir for COVID-19 Treatment: What Are We Missing?
por: Chhatwal, Jagpreet, et al.
Publicado: (2022)

Cost-Effectiveness Analysis of Remdesivir Treatment in COVID-19 Patients Requiring Low-Flow Oxygen Therapy: Payer Perspective in Turkey
por: Oksuz, Ergun, et al.
Publicado: (2021)

A Cost-Effectiveness Analysis of Remdesivir for the Treatment of Hospitalized Patients With COVID-19 in England and Wales
por: Rafia, Rachid, et al.
Publicado: (2022)

Remdesivir may be cost saving in eligible patients during COVID-19 infections in Germany
Publicado: (2021)

Burden and Treatment of Achondroplasia: A Systematic Literature Review
por: Murton, Molly C., et al.
Publicado: (2023)

Remdesivir appears to save costs in COVID-19 patients on low-flow oxygen therapy in Turkey
Publicado: (2021)

POSC41 Cost-Effectiveness Analysis of Remdesivir for the Treatment of COVID-19 Hospitalized Adults in Mexico
por: Ponce-de-León, A, et al.
Publicado: (2022)

EE527 Cost-Effectiveness and Budget Impact Analysis of Remdesivir for the Treatment of COVID-19 in Greece
por: Athanasakis, K, et al.
Publicado: (2022)

519. Early Transition to Outpatient Remdesivir Increases Patient Satisfaction while Decreasing Hospital Costs
por: Chesdachai, Supavit, et al.
Publicado: (2023)

Cost utility analysis of Remdesivir and Dexamethasone treatment for hospitalised COVID-19 patients - a hypothetical study
por: Carta, Andrea, et al.
Publicado: (2021)

Cost-Effectiveness of Combination of Baricitinib and Remdesivir in Hospitalized Patients with COVID-19 in the United States: A Modelling Study
por: Kelton, Kari, et al.
Publicado: (2021)

Assessing the evidence on remdesivir
por: Núñez, Isaac, et al.
Publicado: (2021)

Assessing the evidence on remdesivir
por: Trøseid, Marius, et al.
Publicado: (2021)

Health-economic modelling of cost savings due to the use of rezafungin based on a German cost-of-illness study of candidiasis
por: Jeck, Julia, et al.
Publicado: (2023)

Remdesivir and COVID-19
por: Ferrara, Francesco, et al.
Publicado: (2020)

Remdesivir for COVID-19
Publicado: (2020)

Remdesivir and COVID-19
por: Glaus, Matthew J, et al.
Publicado: (2020)

Remdesivir and COVID-19
por: Wang, Lei-Yun, et al.
Publicado: (2020)

Remdesivir and COVID-19
por: Dennis, Alicia
Publicado: (2020)

Remdesivir and COVID-19
por: Edwards, Jessie K, et al.
Publicado: (2020)

Remdesivir – Current evidence & perspective in management of COVID-19 infection
por: Bajpai, Jyoti, et al.
Publicado: (2021)

Addendum to Systematic Review of Remdesivir for the Treatment of COVID-19
por: Musa, Arif, et al.
Publicado: (2020)

Resource Utilization and Costs of Age-Related Macular Degeneration
por: Halpern, Michael T., et al.
Publicado: (2006)

Remdesivir in Coronavirus Disease 2019 (COVID-19) treatment: a review of evidence
por: Lin, Hui Xian Jaime, et al.
Publicado: (2021)

Reducing laboratory costs through rational testing in suspected pre-eclampsia
por: Jakes, Adam Daniel, et al.
Publicado: (2022)

Use of anti-viral therapies in hospitalised COVID-19 patients in the United Arab Emirates: a cost-effectiveness and health-care resource use analysis
por: Subhi, Ahmad, et al.
Publicado: (2023)

Cost-Effectiveness Analyses, Costs and Resource Use, and Health-Related Quality of Life in Patients with Follicular or Marginal Zone Lymphoma: Systematic Reviews
por: Monga, Neerav, et al.
Publicado: (2020)

The costs, resource use and cost-effectiveness of Clinical Nurse Specialist–led interventions for patients with palliative care needs: A systematic review of international evidence
por: Salamanca-Balen, Natalia, et al.
Publicado: (2017)

Remdesivir for the treatment of COVID-19: a systematic review and meta-analysis
por: Lee, Todd C., et al.
Publicado: (2022)

Remdesivir for patients with COVID-19
por: Wu, Peter E., et al.
Publicado: (2021)

EE410 Cost-Effectiveness Analysis of Remdesivir for the Treatment of COVID-19 Hospitalized Adults in Three Countries of LATAM: Argentina, Chile, and Colombia
por: Montejano, R, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_u3vkrkj5jgfbof13desep6unao